- Home
- CG vs GMAB Comparison
CG vs GMAB Comparison
Compare CG & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CG
- GMAB
- Stock Information
- Founded
- CG 1987
- GMAB 1999
- Country
- CG United States
- GMAB Denmark
- Employees
- CG N/A
- GMAB N/A
- Industry
- CG Investment Managers
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CG Finance
- GMAB Health Care
- Exchange
- CG Nasdaq
- GMAB Nasdaq
- Market Cap
- CG 14.0B
- GMAB 12.8B
- IPO Year
- CG 2012
- GMAB N/A
- Fundamental
- Price
- CG $45.20
- GMAB $20.95
- Analyst Decision
- CG Hold
- GMAB Buy
- Analyst Count
- CG 15
- GMAB 9
- Target Price
- CG $48.54
- GMAB $39.17
- AVG Volume (30 Days)
- CG 2.8M
- GMAB 1.5M
- Earning Date
- CG 05-08-2025
- GMAB 05-08-2025
- Dividend Yield
- CG 3.10%
- GMAB N/A
- EPS Growth
- CG N/A
- GMAB 276.13
- EPS
- CG 2.94
- GMAB 18.36
- Revenue
- CG $5,038,700,000.00
- GMAB $3,230,902,140.00
- Revenue This Year
- CG N/A
- GMAB $17.69
- Revenue Next Year
- CG $19.24
- GMAB $14.81
- P/E Ratio
- CG $15.35
- GMAB $11.30
- Revenue Growth
- CG 127.13
- GMAB 25.21
- 52 Week Low
- CG $33.02
- GMAB $17.24
- 52 Week High
- CG $57.50
- GMAB $28.96
- Technical
- Relative Strength Index (RSI)
- CG 56.17
- GMAB 55.72
- Support Level
- CG $43.19
- GMAB $20.73
- Resistance Level
- CG $46.44
- GMAB $21.42
- Average True Range (ATR)
- CG 1.42
- GMAB 0.45
- MACD
- CG -0.07
- GMAB 0.11
- Stochastic Oscillator
- CG 42.23
- GMAB 81.62
About CG The Carlyle Group Inc.
The Carlyle Group is one of the world's largest alternative-asset managers, with $447.4 billion in total AUM, including $313.6 billion in fee-earning AUM, at the end of September 2024. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure, and natural resources funds (accounting for 33% of fee-earning AUM and 57% of base management fees during 2023), global credit (51% and 27%) and investment solutions (16% and 16%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving more than 2,900 active carry fund investors from 88 countries.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.